Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: Further analysis of secondary end-points of a randomized clinical trial

European Journal of Clinical Investigation

Volumn 33, Issue 3, 2003, Pages 209-215

  Vermeulen, E G J ^a,c   Rauwerda, J A ^a   Van Den Berg, M ^a   De Jong, S C ^a   Schalkwijk, C ^a   Twisk, J W R ^b   Stehouwer, C D A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GELRE HOSPITALS   (Netherlands)

Author keywords

Endothelial markers; Homocysteine; Microalbuminuria; Randomized clinical trial; Vitamin treatment

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CELL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRIDOXINE; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

AGE; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; GENDER; HUMAN; HYPERHOMOCYSTEINEMIA; MICROALBUMINURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY EXCRETION; VITAMIN SUPPLEMENTATION;

ADULT; ALBUMINURIA; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENDOTHELIUM; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; MIDDLE AGED; VITAMIN B 6;

EID: 0037356945     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01135.x     Document Type: Article

References (35)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
2. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
3. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
4. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-41.
5. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst (e) inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-21.
6. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY et al. Hyperhomocyst (e) inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542-4.
7. Valk-de Roo GW, Stehouwer CDA, Lambert J, Schalkwijk CG, van der Mooren MJ, Kluft C et al. Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women. Clin Chem 1999;45:1200-5.
8. Hanratty CG, McAuley DF, McGrath LT, Young IS, Johnston GD. Hyperhomocysteinaemia in young adults is not associated with impaired endothelial function. Clin Sci (Colch) 2001;100:67-72.
9. Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM et al. Serum homocysteine levels are associated with the development of (micro) albuminuria: the Hoorn study. Arterioscler Thromb Vasc Biol 2001;21:74-81.
10. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998;54:203-9.
11. de Jong SC, Stehouwer CDA, vd Berg M, Vischer UM, Rauwerda JA, Emeis JJ. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost 1997;78:1332-7.
12. Becker A, van Hinsbergh VWM, Kostense PJ, Jager A, Dekker JM, Nijpels G et al. Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule-1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects. Eur J Clin Invest 2000;30:763-70.
13. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odekerken DA et al. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999;22:125-32.
14. Vermeulen EGJ, Stehouwer CDA, Twisk JWR, vd Berg M, de Jong SC, Mackaay AJC et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517-22.
15. van Dijk RAJM, Rauwerda JA, Steyn M, Twisk JWR, Stehouwer CDA. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness. Arterioscl Thromb Vasc Biol 2001;21:2072-9.
16. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999;42:351-7.
17. Zeger SL, Liang KY, Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
18. Twisk JWR. Different statistical models to analyze epidemiological observational longitudinal data, an example from the Amsterdam Growth and Health Study. Int J Sports Med 1997;18 (Suppl. 3):S216-24.
19. Viberti GC, Jarrett RJ, Keen H. Microalbuminuria as prediction of nephropathy in diabetics. Lancet 1982;2:611.
20. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60.
21. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999:617-24.
22. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey Lancet 1988;2:530-3.
23. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992-7.
24. Boulatov VA, Stenehjem A, Os I. Association between albumin: creatinine ratio and 24-hour ambulatory blood pressure in essential hypertension. Am J Hypertens 2001;14:338-44.
25. Stehouwer CDA, Lambert J, Donker AJ, van Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997;34:55-68.
26. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989;1:461-3.
27. Kumagai H, Katoh S, Hirosawa K, Kimura M, Hishida A, Ikegaya N. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002;62(4):1219-28.
28. Stehouwer CDA. Is measurement of endothelial dysfunction clinically useful? Eur J Clin Invest 1999;29:459-61.
29. Jager A, van Hinsbergh VWM, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM et al. Increased levels of soluble vascular cell adhesion molecule-1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 2000;49:485-91.
30. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-8.
31. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
32. Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh M. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001;85:623-7.
33. van den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25:176-81.
34. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
35. Schalkwijk CG, Smulders RA, Lambert J, Donker AJ, Stehouwer CDA. ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type 1 diabetic patients. Eur J Clin Invest 2000, 853-60.